Steve Skarky
Psychiatry · Oklahoma City, OKNPI 1225145378
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 188 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 16.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,264 and has fallen 57.5% since, to $537 in 2025.
Across 188 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$653
- Otsuka America Pharmaceutical, Inc.$491
- AbbVie$408
- Lundbeck LLC$402
- Takeda Pharmaceuticals U.S.A., Inc.$388
- Axsome Therapeutics, Inc.$240
- plus $1K from 29 others
What the payments were for
- Food & beverage$4,022100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 21 | $653 |
| Otsuka America Pharmaceutical, Inc. | 25 | $491 |
| AbbVie(2 entities) | 20 | $408 |
| Lundbeck LLC | 20 | $402 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $388 |
| Axsome Therapeutics, Inc. | 12 | $240 |
| Corium, LLC | 11 | $204 |
| Noven Therapeutics, LLC | 8 | $190 |
| Merck | 8 | $136 |
| Teva Pharmaceuticals USA, Inc. | 5 | $92 |
| Stryker | 2 | $89 |
| Novo Nordisk | 4 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $59 |
| Paratek Pharmaceuticals, Inc. | 3 | $51 |
| Sunovion Pharmaceuticals Inc. | 2 | $45 |
| Alkermes, Inc. | 2 | $44 |
| Adlon Therapeutics L.p. | 3 | $41 |
| Pacira Pharmaceuticals Incorporated | 2 | $40 |
| Lilly USA, LLC | 2 | $38 |
| Vertex | 2 | $36 |
| AstraZeneca | 2 | $31 |
| Baxter Healthcare | 1 | $28 |
| Medacta USA, Inc. | 1 | $26 |
| ERMI LLC | 1 | $25 |
| Corcept Therapeutics | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| GSK | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Pylant Medical | 1 | $16 |
| Exact Sciences | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,022 in reported general payments places this provider in the 85th percentile of 328 psychiatry providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 16 | $1,014 |
| Bupropion XlBupropion Hcl | 23 | $597 |
| Benztropine Mesylate | 16 | $363 |
| Methylphenidate Hcl | 13 | $311 |
| Diazepam | 23 | $248 |
| Lorazepam | 14 | $209 |
| Lamotrigine | 20 | $201 |
| Clonazepam | 25 | $201 |
| Alprazolam | 25 | $175 |
| Sertraline Hcl | 15 | $94 |
| Trazodone Hcl | 11 | $55 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Oklahoma City
- Willis HollowayOklahoma City$92K
- Adonis Al BotrosOklahoma City$73K
- Marvin PeytonOklahoma City$60K
- Josephine DeguzmanOklahoma City$38K
- Haisam Al KhouriOklahoma City$10K
- Patrick HornOklahoma City$8K
- Shreekuma VinekarOklahoma City$7K
- Relindis TitaOklahoma City$6K
- Janita ArdisOklahoma City$6K
- Fiona LiOklahoma City$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.